JP2021521275A - Ｎｋ細胞結合抗体融合構築物 - Google Patents

Ｎｋ細胞結合抗体融合構築物 Download PDF

Info

Publication number
JP2021521275A
JP2021521275A JP2021504593A JP2021504593A JP2021521275A JP 2021521275 A JP2021521275 A JP 2021521275A JP 2021504593 A JP2021504593 A JP 2021504593A JP 2021504593 A JP2021504593 A JP 2021504593A JP 2021521275 A JP2021521275 A JP 2021521275A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
cd16a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021504593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521275A5 (https=
JPWO2019198051A5 (https=
Inventor
マイケル テサシュ，
マイケル テサシュ，
クリスチナ エルヴァンガー，
クリスチナ エルヴァンガー，
イヴィカ フセック，
イヴィカ フセック，
ウーヴェ レウシュ，
ウーヴェ レウシュ，
トシュテン ロス，
トシュテン ロス，
ヨアヒム コッホ，
ヨアヒム コッホ，
エーリヒ ラヤコヴィッチ，
エーリヒ ラヤコヴィッチ，
マルティン トレダー，
マルティン トレダー，
Original Assignee
アフィメド ゲーエムベーハー
アフィメド ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アフィメド ゲーエムベーハー, アフィメド ゲーエムベーハー filed Critical アフィメド ゲーエムベーハー
Publication of JP2021521275A publication Critical patent/JP2021521275A/ja
Publication of JP2021521275A5 publication Critical patent/JP2021521275A5/ja
Publication of JPWO2019198051A5 publication Critical patent/JPWO2019198051A5/ja
Priority to JP2025006634A priority Critical patent/JP2025081307A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021504593A 2018-04-13 2019-04-12 Ｎｋ細胞結合抗体融合構築物 Pending JP2021521275A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025006634A JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18167384 2018-04-13
EP18167385.6 2018-04-13
EP18167385 2018-04-13
EP18167384.9 2018-04-13
EP18190662.9 2018-08-24
EP18190662 2018-08-24
EP18190661.1 2018-08-24
EP18190661 2018-08-24
PCT/IB2019/053040 WO2019198051A2 (en) 2018-04-13 2019-04-12 Nk cell engaging antibody fusion constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025006634A Division JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Publications (3)

Publication Number Publication Date
JP2021521275A true JP2021521275A (ja) 2021-08-26
JP2021521275A5 JP2021521275A5 (https=) 2022-04-20
JPWO2019198051A5 JPWO2019198051A5 (https=) 2022-04-20

Family

ID=66625219

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504593A Pending JP2021521275A (ja) 2018-04-13 2019-04-12 Ｎｋ細胞結合抗体融合構築物
JP2025006634A Pending JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025006634A Pending JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Country Status (21)

Country Link
US (3) US11001633B2 (https=)
EP (1) EP3774914A2 (https=)
JP (2) JP2021521275A (https=)
KR (1) KR20200143436A (https=)
CN (3) CN113817066A (https=)
AU (2) AU2019252970A1 (https=)
BR (1) BR112020020828A2 (https=)
CA (1) CA3095373A1 (https=)
CL (2) CL2020002625A1 (https=)
CO (1) CO2020014167A2 (https=)
CR (1) CR20200549A (https=)
IL (1) IL277925A (https=)
MA (1) MA52227A (https=)
MX (1) MX2020010728A (https=)
PE (1) PE20201346A1 (https=)
PH (1) PH12020551664B1 (https=)
RU (1) RU2022105827A (https=)
SG (1) SG11202010064QA (https=)
TW (1) TW202012441A (https=)
WO (1) WO2019198051A2 (https=)
ZA (1) ZA202006325B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220396635A1 (en) * 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
EP4073117A1 (en) * 2019-12-10 2022-10-19 Institut Pasteur New antibody blocking human fcgriiia and fcgriiib
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
KR20220119467A (ko) 2019-12-27 2022-08-29 아피메트 게엠베하 이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
US20230322953A1 (en) * 2020-06-30 2023-10-12 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
IL302402A (en) * 2020-11-08 2023-06-01 Seagen Inc Combined treatment
EP4255931A1 (en) * 2020-12-03 2023-10-11 Amgen Inc. Immunoglobuline constructs with multiple binding domains
WO2022161314A1 (zh) * 2021-01-27 2022-08-04 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途
EP4330436A1 (en) 2021-04-30 2024-03-06 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
CA3233085A1 (en) * 2021-09-24 2023-03-30 Synergy Imt, Inc. Composition of recombinant antigen binding molecules and method of making and using thereof
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders
JP2024543828A (ja) 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性ｃｄ１６ａバインダー
CN116284385A (zh) * 2021-12-07 2023-06-23 信达细胞制药(苏州)有限公司 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
JP2025528087A (ja) * 2022-08-05 2025-08-26 チマゲン・バイオサイエンシズ，リミテッド 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体
JP2025531168A (ja) * 2022-09-14 2025-09-19 大塚製薬株式会社 Ｐｄ－１アゴニスト抗体
WO2024165028A1 (en) * 2023-02-06 2024-08-15 Concept To Medicine Biotech Co., Ltd. Anti-cd16a antibodies and uses thereof
WO2024186092A1 (ko) * 2023-03-06 2024-09-12 주식회사 드노보 바이오테라퓨틱스 신규한 항-cd16 항체 및 이의 용도
WO2025257588A1 (en) * 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2008541714A (ja) * 2005-05-26 2008-11-27 アフィメート テラポイティクス アーゲー 抗ｃｄ１６結合分子
EP2361936A1 (en) * 2010-02-25 2011-08-31 Affimed Therapeutics AG Antigen-binding molecule and uses thereof
JP2014534242A (ja) * 2011-11-15 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｂｃｍａおよびｃｄ３に対する結合分子
JP2016508153A (ja) * 2013-01-10 2016-03-17 ゲンマブ エー／エス 不活性フォーマット
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
EP3091031A1 (en) * 2015-05-04 2016-11-09 Affimed GmbH Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
WO2016177846A1 (en) * 2015-05-04 2016-11-10 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
WO2016207278A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
WO2017031104A1 (en) * 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
CN106632681A (zh) * 2016-10-11 2017-05-10 北京东方百泰生物科技有限公司 抗egfr 和抗cd3双特异抗体及其应用
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
JP2018509175A (ja) * 2014-12-22 2018-04-05 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． 二重特異性四価抗体並びにその製作及び使用方法
WO2018158349A1 (en) * 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2406284B9 (en) 2009-03-10 2017-03-01 Biogen MA Inc. Anti-bcma antibodies
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
US9676857B2 (en) 2012-03-16 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble engineered monomeric Fc
JP6694712B2 (ja) 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2008541714A (ja) * 2005-05-26 2008-11-27 アフィメート テラポイティクス アーゲー 抗ｃｄ１６結合分子
EP2361936A1 (en) * 2010-02-25 2011-08-31 Affimed Therapeutics AG Antigen-binding molecule and uses thereof
JP2014534242A (ja) * 2011-11-15 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｂｃｍａおよびｃｄ３に対する結合分子
JP2016508153A (ja) * 2013-01-10 2016-03-17 ゲンマブ エー／エス 不活性フォーマット
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
JP2018509175A (ja) * 2014-12-22 2018-04-05 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． 二重特異性四価抗体並びにその製作及び使用方法
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
EP3091031A1 (en) * 2015-05-04 2016-11-09 Affimed GmbH Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
WO2016177846A1 (en) * 2015-05-04 2016-11-10 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
WO2016207278A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
WO2017031104A1 (en) * 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
CN106632681A (zh) * 2016-10-11 2017-05-10 北京东方百泰生物科技有限公司 抗egfr 和抗cd3双特异抗体及其应用
WO2018158349A1 (en) * 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH", PRESS RELEASE-DECEMBER 11, 2017, JPN6023012260, 2017, ISSN: 0005221623 *
GANTKE, THORSTEN ET AL.: "AFM26-Targeting BCMA for NK cell-mediated immunotherapy of multiple myeloma", 59TH MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, JPN6023012261, 2017, pages 3082, ISSN: 0005221622 *
GANTKE, THORSTEN ET AL.: "Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma", BLOOD, vol. 128(22):4513, JPN6023012259, 2016, pages 1 - 2, ISSN: 0005221624 *
REUSCH, UWE ET AL.: "A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD", MABS, vol. 6(3), JPN6023012258, 2014, pages 727 - 738, ISSN: 0005221625 *

Also Published As

Publication number Publication date
AU2026200541A1 (en) 2026-02-19
CO2020014167A2 (es) 2021-04-08
CL2020002625A1 (es) 2021-02-19
RU2022105827A (ru) 2022-04-05
SG11202010064QA (en) 2020-11-27
MA52227A (fr) 2021-04-21
CN112119097B (zh) 2021-10-15
KR20200143436A (ko) 2020-12-23
BR112020020828A2 (pt) 2021-01-19
CR20200549A (es) 2021-03-18
CA3095373A1 (en) 2019-10-17
MX2020010728A (es) 2020-11-06
WO2019198051A2 (en) 2019-10-17
CN113880952A (zh) 2022-01-04
ZA202006325B (en) 2025-12-17
TW202012441A (zh) 2020-04-01
CN112119097A (zh) 2020-12-22
CN113817066A (zh) 2021-12-21
EP3774914A2 (en) 2021-02-17
JP2025081307A (ja) 2025-05-27
US20240294647A1 (en) 2024-09-05
PH12020551664B1 (en) 2023-05-19
US20200109202A1 (en) 2020-04-09
US20210253698A1 (en) 2021-08-19
PH12020551664A1 (en) 2021-12-13
PE20201346A1 (es) 2020-11-25
IL277925A (en) 2020-11-30
WO2019198051A3 (en) 2019-11-14
CL2023001085A1 (es) 2023-10-06
AU2019252970A1 (en) 2020-11-26
US11001633B2 (en) 2021-05-11

Similar Documents

Publication Publication Date Title
US20240294647A1 (en) Uses of nk cell engaging antibody fusion constructs for treatments
US20230055445A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
JP7010854B2 (ja) 二重特異性チェックポイント阻害剤抗体
CN110382539B (zh) 用于cd16a定向的nk细胞结合的串联双抗体
JP2021521779A (ja) ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＬＡＧ−３抗原結合ドメインを含む、ＬＡＧ−３を標的とするヘテロ二量体融合タンパク質
JP2020529832A (ja) ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
JP2019533444A (ja) ＩＬ−１５／ＩＬ−１５ＲアルファＦｃ融合タンパク質およびＰＤ−１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
JP7080219B2 (ja) 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
CN114127112A (zh) 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
JP2025512391A (ja) Ｐｄ－ｌ１、ｐｄ－ｌ２及び／またはｃｄ２８と結合する抗体
RU2774711C2 (ru) Слитые конструкции антител для вовлечения nk-клеток
JP7853939B2 (ja) 二重特異性チェックポイント阻害剤抗体
HK40066389A (zh) 自然杀伤细胞接合抗体融合构建体
HK40066055A (zh) 自然杀伤细胞接合抗体融合构建体
HK40034204B (en) Nk cell engaging antibody fusion constructs
HK40034204A (en) Nk cell engaging antibody fusion constructs
HK40016394B (zh) 双特异性检查点抑制剂抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220412

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240917